Stargardt Disease Drug Tinlarebant Achieves Primary Endpoint in Pivotal Phase 3 Trial; NDA Filing Expected Q2 2026
BLTE has more than doubled off its 52-week low of $49.
Summary
Belite Bio announced highly positive topline results from its pivotal Phase 3 DRAGON trial for tinlarebant, a potential first-in-class therapy for Stargardt disease. The trial met its primary efficacy endpoint, demonstrating a statistically significant 35.7% reduction in the growth rate of macular lesions (p=0.0033). This is a major de-risking event for the company, as Stargardt disease currently has no approved treatment. The company is on track to submit a New Drug Application (NDA) to the FDA in the second quarter of 2026. Additionally, Belite Bio completed enrollment for its Phase 3 PHOENIX trial for Geographic Atrophy and reported a strong cash position of $352.9 million as of year-end 2025, following a $402 million public offering. This robust financial standing provides significant runway for commercialization preparations and pipeline development. Traders will be closely watching the upcoming NDA submission and potential interim analysis for the PHOENIX trial.
At the time of this announcement, BLTE was trading at $190.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $49.00 to $200.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.